Novo Nordisk (NVO) won a key case Thursday to stop some compounding pharmacies from selling knockoff versions of its blockbuster GLP-1 drugs. But it won't end all compounding offerings. The ...

Novo Nordisk A/S’s share was trading at $70.73 as of June 24th. NVO’s trailing and forward P/E were 19.24 and 17.09, respectively, according to Yahoo Finance.

Novo Nordisk's GLP-1 Market Growth (Novo Nordisk's Q1-2025 Investor Presentation) The next risk is drug pricing reform in the US, as it could pressure margins.